In 2017, deal volume in the biopharma space slowed for the third consecutive year. Value in all of the pharma and life sciences sector totaled only about $181 billion, down 23% from a year earlier, according to PricewaterhouseCoopers.

But according to Intec Pharma Ltd. (NTEC) Chief Executive Officer and Vice Chairman Jeffrey Meckler, a slowdown one year doesn't necessarily portend a slowdown the next year. Rather, innovation is often what drives mergers and acquisitions in biopharma.

"Where there's real innovation, there's always someone willing to pay for it," Meckler said.

More from Mergers and Acquisitions

Goldman Names Dees Co-Head of Investment Banking

Goldman Names Dees Co-Head of Investment Banking

All-Male Boards Could Face New Pressure From Shareholder Adviser ISS

All-Male Boards Could Face New Pressure From Shareholder Adviser ISS

3 Reasons Apple or Alphabet Should Consider Buying Tesla

3 Reasons Apple or Alphabet Should Consider Buying Tesla

Kraft Heinz Has an 'Unsustainable Diet,' Says Morgan Stanley

Kraft Heinz Has an 'Unsustainable Diet,' Says Morgan Stanley

Jim Cramer: The Market Thinks China Will Blink First in Trade War

Jim Cramer: The Market Thinks China Will Blink First in Trade War